The company has filed a reasonable best efforts public offering of up to 2.4M shares of its common stock at an assumed public offering price of $2.08 per share, the last reported sale price of its common stock as reported on NYSE American on August 12.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGEN:
- Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
- Oragenics shows ONP-002 stable across wide temperature range
- Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
- Oragenics announces ONP-002 completes FDA-required Genotoxicity Study
- Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study